In case you hadn't already heard about this. Now you have:
https://endpts.com/daiichi-sankyo-disappointed-as-fda-experts-spurn-aml-drug-but-vote-in-favor-of-rare-tumor-drug/
https://www.reuters.com/article/us-daiichi-sankyo-fda/fda-advisory-panel-votes-against-daiichi-sankyos-cancer-treatment-idUSKCN1SK2JP
https://www.fiercebiotech.com/biotech/daiichi-s-leukemia-drug-falls-amid-fda-adcomm-s-trial-concerns
https://finance.yahoo.com/news/daiichi-sankyo-announces-outcome-fda-220200236.html
https://www.biospace.com/article/daiichi-sankyo-receives-a-yes-and-no-from-fda-advisory-panel/
https://www.evaluate.com/vantage/articles/news/snippets/us-backs-only-one-two-daiichi-oncology-projects-only-beginning
Wow.
No comments:
Post a Comment